At Regional Cancer Care Associates, patients have access to a wide range of services for cancers of the blood and blood-forming tissues. Regional Cancer Care Associates patients in New Jersey, Connecticut, Maryland, and the Washington, D.C. area can receive the hematology services they need in a location convenient for them. Our hematologists treat blood-based cancers in state-of-the-art facilities and proudly maintain a compassionate, personalized approach to care.
A hematologic condition is one that affects the blood, and malignant hematology focuses on evaluating and treating types of blood cancers. Patients with malignant blood disorders are monitored closely after diagnosis and, depending on their diagnosis, may be treated with a variety of therapies, including immunotherapy and chemotherapy. Malignant hematologic disorders may involve the following:
At Regional Cancer Care Associates, our board-certified hematologists and full clinical team are dedicated to improving the quality of life and overall wellbeing of our patients. Our specialists are experienced in diagnosing different blood disorders and providing first-class treatment that’s based on the latest medical evidence and the individual needs of each patient.
In our state-of-the-art facilities, we treat patients with a broad spectrum of blood cancers, including the following types:
White blood cells are vital to the body’s defense against infection. If the body produces an abnormal amount of white blood cells, this indicates a disorder. Myeloid disorders include:
Myeloproliferative Neoplasms (MPNs) are disorders characterized by an overproduction of blood cells. They’re typically chronic and may produce significant symptoms in some patients. These conditions include:
Myelodysplastic syndrome is a fairly common blood disorder in which blood cells in the bone marrow do not mature or develop into healthy blood cells. This condition frequently recurs in the elderly and is expertly monitored and treated in a variety of ways, depending on its severity.
This condition occurs when the body cannot produce enough new blood cells. This condition ranges from mild to severe, may develop at any age, and can slowly progress over time.
A rare, acquired disorder, this condition occurs when a change in stem cells causes the body to produce cells that are missing protective proteins. This results in the destruction of red blood cells (hemolysis), blood clots (thrombosis), and impaired bone marrow function.
Acute Myeloid Leukemia begins in the bone marrow and often quickly progresses into the blood. This condition can spread to other parts of the body, such as the lymph nodes, liver, and central nervous system.
This blood cancer originates in blood-forming tissues, which are found in places like the lymphatic system and bone marrow. It develops when blood cells grow and divide out of control, crowding healthy blood cells and leading to a decrease in platelets, red blood cells, and white blood cells. While the exact cause is unknown, scientists believe leukemia is the result of environmental and genetic factors. Symptoms vary depending on the type of leukemia, with the most major types including:
Also known as Kahler’s disease, multiple myeloma forms in the bone marrow’s plasma cells, a type of white blood cell that helps the body fight infection. Considered a malignant plasma cell disorder, the condition is characterized by groups of abnormal plasma cells dividing and multiplying, leading to kidney, bone, and immune system damage and decreasing a patient’s red blood cell count.
If you or a loved one needs treatment for a malignant blood disorder, access advanced care from Regional Cancer Care Associates. Our personalized, patient-focused hematology services extend throughout our wide provider network across NJ, CT, MD, and the Washington, D.C. area. To schedule an appointment or learn more about our malignant hematology treatments, contact us today.
Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.